Phase 3 Readout~month

Phase 3 Topline: A Single-Arm, Open-Label, Safety Study in Patients With Generalized Lipodystrophy Switching From Met

Indication
Generalized Lipodystrophy

Other upcoming events for REGN

Phase 2 StartPhase 2 Start: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of ALN-CIDEB in Adults With Fibrotic
Phase 2 StartPhase 2 Start: A Phase 1/2 Open-Label, Safety and Efficacy Study of Neoadjuvant Fianlimab (Anti-LAG-3 Antibody) in
Phase 2 StartPhase 2 Start: A Phase 1/2 Open-Label, Safety and Efficacy Study of Neoadjuvant Fianlimab (Anti-LAG-3 Antibody) in
Phase 3 ReadoutPhase 3 Topline: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥
Phase 3 ReadoutPhase 3 Topline: A Randomized, Open-Label, C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozel

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Single-Arm, Open-Label, Safety Study in Patients With Generalized Lipodystrophy Switching From Met — REGN Phase 3 Readout | BioSniper